TSH Biopharm Corporation Limited (TPEX:8432)
Taiwan · Delayed Price · Currency is TWD 61.50
+0.10 (0.16%)
Nov 10, 2026, 1:30 PM CST
TSH Biopharm Corporation Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,531 | 1,337 | 1,116 | 810.92 | 741.07 | 413.48 | |
Revenue Growth | 20.56% | 19.79% | 37.59% | 9.43% | 79.22% | -7.68% |
Cost of Revenue | 723.96 | 655.79 | 532.95 | 411.02 | 351.2 | 166.13 |
Gross Profit | 807.28 | 680.74 | 582.76 | 399.9 | 389.87 | 247.36 |
Selling, General & Admin | 459.27 | 436.86 | 384.16 | 313.39 | 289.71 | 168.33 |
Research & Development | 30.78 | 24.62 | 27.99 | 24.81 | 31.09 | 23.52 |
Operating Expenses | 489 | 462.37 | 412.91 | 336.27 | 323.85 | 191.74 |
Operating Income | 318.28 | 218.37 | 169.86 | 63.63 | 66.03 | 55.62 |
Interest Expense | -0.78 | -0.8 | -0.46 | -0.69 | -0.7 | -0.08 |
Interest & Investment Income | 16.55 | 14.83 | 11.98 | 13.06 | 9.71 | 8.46 |
Currency Exchange Gain (Loss) | -0.06 | -0.06 | 0.33 | -0.43 | 6.39 | -1.26 |
Other Non Operating Income (Expenses) | 2.1 | 1.33 | 1.39 | 0.56 | -0.13 | -1.23 |
EBT Excluding Unusual Items | 336.09 | 233.67 | 183.1 | 76.13 | 81.3 | 61.51 |
Gain (Loss) on Sale of Investments | 1.11 | 1.11 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.87 | -0.04 | -0.06 | -0 |
Asset Writedown | - | - | -8.8 | - | - | - |
Other Unusual Items | - | - | - | - | - | 0.05 |
Pretax Income | 337.2 | 234.79 | 173.43 | 76.09 | 81.24 | 61.55 |
Income Tax Expense | 54.09 | 46.97 | 39.29 | 11.11 | 15.1 | 14.44 |
Earnings From Continuing Operations | 283.11 | 187.82 | 134.15 | 64.98 | 66.14 | 47.11 |
Minority Interest in Earnings | -73.26 | -48.56 | -21.06 | -2.99 | -4.25 | - |
Net Income | 209.85 | 139.26 | 113.09 | 61.99 | 61.89 | 47.11 |
Net Income to Common | 209.85 | 139.26 | 113.09 | 61.99 | 61.89 | 47.11 |
Net Income Growth | 67.85% | 23.14% | 82.44% | 0.16% | 31.38% | -23.49% |
Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 | 38 |
Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 | 38 |
Shares Change | 0.09% | 0.05% | 0.04% | -0.05% | 0.05% | 0.01% |
EPS (Basic) | 5.46 | 3.63 | 2.95 | 1.61 | 1.61 | 1.23 |
EPS (Diluted) | 5.45 | 3.62 | 2.94 | 1.61 | 1.61 | 1.23 |
EPS Growth | 67.71% | 23.13% | 82.61% | 0% | 31.23% | -23.32% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 245.89 | 135 | 182.04 | 28.49 | 30.62 | 68.33 |
Free Cash Flow Per Share | 6.39 | 3.51 | 4.74 | 0.74 | 0.80 | 1.78 |
Dividend Per Share | 2.610 | 2.610 | 2.120 | 1.280 | 1.600 | 1.500 |
Dividend Growth | 23.11% | 23.11% | 65.63% | -20.00% | 6.67% | -16.67% |
Gross Margin | 52.72% | 50.93% | 52.23% | 49.31% | 52.61% | 59.82% |
Operating Margin | 20.79% | 16.34% | 15.22% | 7.85% | 8.91% | 13.45% |
Profit Margin | 13.71% | 10.42% | 10.14% | 7.64% | 8.35% | 11.39% |
Free Cash Flow Margin | 16.06% | 10.10% | 16.32% | 3.51% | 4.13% | 16.52% |
EBITDA | 332.17 | 231.38 | 185.11 | 77.65 | 79.28 | 60.87 |
EBITDA Margin | 21.69% | 17.31% | 16.59% | 9.58% | 10.70% | 14.72% |
D&A For EBITDA | 13.89 | 13.01 | 15.26 | 14.02 | 13.25 | 5.26 |
EBIT | 318.28 | 218.37 | 169.86 | 63.63 | 66.03 | 55.62 |
EBIT Margin | 20.79% | 16.34% | 15.22% | 7.85% | 8.91% | 13.45% |
Effective Tax Rate | 16.04% | 20.00% | 22.65% | 14.61% | 18.58% | 23.46% |